Menu Back toFDA Science Strategies: Purposeful Scientific Leadership to Advance Innovation and Improve Patient Outcomes

DIA 2021 Global Annual Meeting

FDA Science Strategies: Purposeful Scientific Leadership to Advance Innovation and Improve Patient Outcomes

Session Chair(s)

Meghana Chalasani, MHA

Meghana Chalasani, MHA

  • Lead, Science Strategies, Office of New Drugs, CDER
  • FDA, United States
This forum will provide an overview of FDA CDER’s Science Strategies Program. It will also provide an opportunity for stakeholders, including patients and drug developers, to share their experiences, perspectives and priorities to inform FDA’s efforts.
Learning Objective : Describe FDA Center for Drug Evaluation and Research’s Office of New Drugs' efforts to enhance therapeutic-specific strategic planning and scientific leadership; Discuss the opportunities for key stakeholders including, patients, academia, drug developers, health care providers, and payers, to help advance FDA’s therapeutic-specific science strategies.

Speaker(s)

Klaus Romero, MD, MS

Panelist

Klaus Romero, MD, MS

  • Chief Scientific Officer
  • Critical Path Institute (C-Path), United States
Jeffrey Siegel, MD

Panelist

Jeffrey Siegel, MD

  • Director, Office of Drug Evaluation Sciences, Office of New Drugs, CDER
  • FDA, United States
Michelle Campbell, PhD

Panelist

Michelle Campbell, PhD

  • Senior Clinical Analyst for Stakeholder Engagement, ON, OND, CDER
  • FDA, United States
Meaghan Malley

Panelist

Meaghan Malley

  • Senior Project Associate, Kidney Health Initiative
  • ASN Alliance for Kidney Health, United States